12.07.2012 • NewsCO2 emissionsCodexis

Codexis Demonstrates Enzyme-Based Carbon Capture at NCCC

Codexis unveiled results from the pilot-scale demonstration of the company's carbon capture technology conducted at the National Carbon Capture Center (NCCC) in Wilsonville, Alabama.

Codexis developed this patented technology under a license granted by CO2 Solutions.

The field test, on flue gas emitted from a Southern Company's power plant, shows that enzymes have promise to facilitate CO2 capture at coal-fired power plants. This is the largest scale that enzyme-based carbon capture technology has been demonstrated to date, with the equivalent daily capture rate of 1,800 average sized trees per day.

In May 2010, Codexis received $4.7 million from the U.S. Department of Energy's Advanced Research Projects Agency - Energy (ARPA-E) to develop an active enzyme called carbonic anhydrase (CA), which catalyzes the transfer of carbon dioxide in nature and is designed to remove dangerous emissions from coal-fired power plants.

A 2011 National Energy Technology Laboratory (NETL) report estimated that coal-fired power plants account for roughly 37% of total U.S. CO2 emissions and that current state-of-the-art MEA technology to capture CO2 could reduce power-generating capacity by 30%.

Codexis' enzyme-based technology, if successful, could play a role in meeting the proposed new EPA standards (Carbon Pollution Standard for New Power Plants), first published in April 2012 - theoretically capturing up to 90% of CO2 emissions of coal-fired power plants.

Company

Codexis

200 Penobscot Drive
Redwood City

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.